



PRESS RELEASE

For Immediate Release

Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health (NIH)

Two-year program to study reliable markers for non-invasive assessment of liver fibrosis

DENVER, Colo. — December 17, 2007 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it has entered into a cooperative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

The two-year study will use the Corgenix Hyaluronic Acid (HA) test kit alone and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in non-alcoholic steatohepatitis (NASH) patients. NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-NIDDK study is focused on developing a non-invasive method of diagnosis.

Nonalcoholic fatty liver disease (NAFLD) is a chronic, typically mild liver condition associated with obesity and insulin resistance, characterized by the presence of fat in the liver. Currently recognized as the most common cause of chronic liver disease in the U.S., NAFLD affects 20-24 percent of Americans. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD associated with inflammation and damage to the liver that can progress to fibrosis and cirrhosis. Approximately 2-5 percent of the U.S. population has NASH.

Since NASH carries a high risk of portal hypertension, liver failure requiring liver transplantation, and hepatocellular carcinoma, it is important to identify these individuals for prognostic and patient management decisions. Currently, the only reliable way to distinguish between NAFLD and NASH is by liver biopsy, which is costly (especially when considering that 60 – 75 million individuals in the U.S. have NAFLD), painful and carries some risk to patients. The aim of this study is to identify non-invasive, reliable markers to identify patients at risk for NASH.

“We are very excited about our collaboration with the NIH. This is a definitive study that will apply our HA product to a very important and clearly under-diagnosed condition that affects a significant percentage of the U.S. population,” said Corgenix President and Chief Executive Officer Douglass Simpson. “With the rate of obesity in the U.S. continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, non-invasive methods for assessment.”

“Nonalcoholic steatohepatitis is a major healthcare problem. It is typically a ‘silent’ disease with few or no symptoms until the disease is advanced,” said Luis Lopez, M.D., Corgenix Chief Medical Officer. “NASH patients whose disease has progressed to cirrhosis have a 7-10 year mortality of up to 25 percent. We believe this study has the potential to make a major difference in literally millions of individuals when completed.”

The Corgenix Hyaluronic Acid test kit has not been cleared by the U.S. Food and Drug Administration for *in vitro* diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, the products shall not be used for diagnostic use as the performance characteristics have not been established. The Hyaluronic Acid test kit is CE-marked for sale in the European Union.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Dan Snyders
Vice President, Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
Fax: 303-623-1191
dan@armadamedical.com